Clinical trial
Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
NCT00412893 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00412893 |
|---|---|
| Title | Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis |
| Official title | A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi. |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Basilea Pharmaceutica International Ltd Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Aspergillosis, Invasive Fungal Infection |
| Intervention type | Drug |
| Interventions | Isavuconazole, Voriconazole |
| Enrollment | 527 |
| Start date | Mar 7, 2007 |
| Primary completion | Mar 28, 2013 |
| Completion | Mar 28, 2013 |
| First posted | Dec 19, 2006 |
| Last update posted | Dec 10, 2024 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Egypt, France, Germany, Hungary, India and 14 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: